VXRT
vs
S&P 500
Over the past 12 months, VXRT has outperformed S&P 500, delivering a return of 40% compared to the S&P 500's 24% growth.
Stocks Performance
VXRT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Performance Gap
VXRT vs S&P 500
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Performance By Year
VXRT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Competitors Performance
Vaxart Inc vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
Schlumberger NV
NYSE:SLB
|
||
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
||
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
Halliburton Co
NYSE:HAL
|
||
LU |
Tenaris SA
MIL:TEN
|
||
IN |
Jio Financial Services Ltd
NSE:JIOFIN
|
Vaxart Inc
Glance View
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.